Functional assessment of CYP3A4 and CYP2C19 genetic polymorphisms on the metabolism of clothianidin in vitro

被引:0
作者
Hu, Yingying [1 ]
Ye, Zhize [2 ]
Wu, Hualu [1 ]
Chen, Xiaohai [1 ]
Xia, Hailun [1 ]
Cai, Jian-ping [3 ]
Hu, Guo-xin [4 ]
Xu, Ren-ai [1 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 1, Nanbaixiang St, Wenzhou 325000, Zhejiang, Peoples R China
[2] Shaoxing Peoples Hosp, Shaoxing, Zhejiang, Peoples R China
[3] Chinese Acad Med Sci, Inst Geriatr Med, Key Lab Geriatr,Beijing Inst Geriatr, Beijing Hosp,Natl Ctr Gerontol,Natl Hlth Commiss, Beijing, Peoples R China
[4] Wenzhou Med Univ, Inst Mol Toxicol & Pharmacol, Sch Pharmaceut Sci, Wenzhou, Zhejiang, Peoples R China
关键词
Clothianidin; Variants; Metabolism; ALLELIC VARIANTS; RAPID METABOLIZER; IDENTIFICATION; GENOTYPE; EXPOSURE; ENZYMES; RISK;
D O I
10.1016/j.cbi.2024.111154
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Clothianidin, classified as a second-generation neonicotinoid, has achieved extensive application due to its high efficacy against insect pests. This broad-spectrum usage has resulted in its frequent detection in environmental surveys. CYP2C19 and CYP3A4 are crucial for converting clothianidin to desmethyl-clothianidin (dm-clothianidin). The expression of these CYP450s can be significantly influenced by genetic polymorphisms. The objective of our research was to examine the catalytic effects of 27 CYP3A4 variants and 31 CYP2C19 variants on the metabolism of clothianidin within recombinant insect microsomes. These variants were assessed through a wellestablished incubation procedure. In addition, the concentration of its metabolite dm-clothianidin was quantified by employing an ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). Lastly, the kinetic parameters of these CYP3A4 and CYP2C19 variants were calculated by applying Michaelis-Menten kinetic analysis to fit the data. The observed changes in enzyme activity were related to the metabolic transformation of clothianidin to dm-clothianidin. In the CYP2C19 metabolic pathway, one variant (CYP2C19.23) showed no notable change in intrinsic clearance (CLint), four variants (CYP2C19.29, .30, .31 and L16F) demonstrated a marked increase in CLint(110.86-183.46 %), and the remaining 25 variants exhibited a considerable decrease in CLint(26.38-89.79 %), with a maximum decrease of 73.62 % (CYP2C19.6). In the CYP3A4 metabolic pathway, 26 variants demonstrated significantly reduced CLint(10.54-52.52 %), with a maximum decrease of 89.46 % (CYP3A4.20). Our results suggested that most variants of CYP3A4 and CYP2C19 significantly altered the enzymatic activities associated with clothianidin metabolism to various degrees. This study provides new insights into assessing the metabolic behavior of pesticides and delivers crucial data that can guide clinical detoxification strategies.
引用
收藏
页数:10
相关论文
共 50 条
[41]   Impact of CYP2C19, CYP2C9, CYP3A4, and FMO3 Genetic Polymorphisms and Sex on the Pharmacokinetics of Voriconazole after Single and Multiple Doses in Healthy Chinese Subjects [J].
Liu, Shuaibing ;
Yao, Xia ;
Tao, Jun ;
Zhao, Shiyu ;
Sun, Suke ;
Wang, Suyun ;
Tian, Xin .
JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (08) :1030-1043
[42]   Association between CYP2C19*2/*3 Polymorphisms and Coronary Heart Disease [J].
Zhang, Ying-ying ;
Zhou, Xin ;
Ji, Wen-jie ;
Liu, Ting ;
Ma, Jing ;
Zhang, Ying ;
Li, Yu-ming .
CURRENT MEDICAL SCIENCE, 2019, 39 (01) :44-51
[43]   Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activity [J].
Mikus, Gerd ;
Foerster, Kathrin Isabelle .
TRANSLATIONAL CANCER RESEARCH, 2017, 6 :S1592-S1599
[44]   A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions [J].
Li, Xia ;
Frechen, Sebastian ;
Moj, Daniel ;
Lehr, Thorsten ;
Taubert, Max ;
Hsin, Chih-hsuan ;
Mikus, Gerd ;
Neuvonen, Pertti J. ;
Olkkola, Klaus T. ;
Saari, Teijo, I ;
Fuhr, Uwe .
CLINICAL PHARMACOKINETICS, 2020, 59 (06) :781-808
[45]   CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms [J].
Zhang, Yuqing ;
Wang, Ziying ;
Wang, Yuchao ;
Jin, Weikai ;
Zhang, Zheyan ;
Jin, Lehao ;
Qian, Jianchang ;
Zheng, Long .
PEERJ, 2024, 12
[46]   Decreased Activity and Genetic Polymorphisms of CYP2C19 in Behcet's Disease [J].
Goktas, Mustafa Tugrul ;
Karaca, Ragip Ozgur ;
Kalkisim, Said ;
Cevik, Lokman ;
Kilic, Levent ;
Akdogan, Ali ;
Babaoglu, Melih O. ;
Bozkurt, Atilla ;
Bertilsson, Leif ;
Yasar, Umit .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 (04) :266-271
[47]   The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects [J].
Tan, Bo ;
Zhang, Yi-Fan ;
Chen, Xiao-Yan ;
Zhao, Xiao-Hua ;
Li, Guo-Xin ;
Zhong, Da-Fang .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (02) :145-151
[48]   Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long-lasting Inhibition of CYP2C19 [J].
Kaartinen, Taavi J. K. ;
Tornio, Aleksi ;
Tapaninen, Tuija ;
Launiainen, Terhi ;
Isoherranen, Nina ;
Niemi, Mikko ;
Backman, Janne T. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (06) :1254-1264
[49]   Effects of CYP2C19 variants on methadone metabolism in vitro [J].
Lan, Tian ;
Yuan, Ling-Jing ;
Hu, Xiao-Xia ;
Zhou, Quan ;
Wang, Jun ;
Huang, Xiang-Xin ;
Dai, Da-Peng ;
Cai, Jian-Ping ;
Hu, Guo-Xin .
DRUG TESTING AND ANALYSIS, 2017, 9 (04) :634-639
[50]   Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population [J].
Hanioka, N. ;
Tsuneto, Y. ;
Saito, Y. ;
Sumada, T. ;
Maekawa, K. ;
Saito, K. ;
Sawada, J. ;
Narimatsu, S. .
XENOBIOTICA, 2007, 37 (04) :342-355